Free tool
FAERS Monitor: Lynavoy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220295 or its brand name (Lynavoy, Linerixibat). Reports on generic versions are filed under their own applications.
Reports
57
Serious
3
5% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use25
- diarrhoea14
- drug interaction11
- drug ineffective9
- abdominal pain upper6
- nausea4
- product dose omission issue3
- pruritus3
- abdominal discomfort2
- constipation2
- intentional product misuse2
- therapeutic product effect incomplete2
- vomiting2
- abdominal distension1
- abdominal pain1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 57 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,102 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug interactionSignal | 11 | 25.6 | 15.0 | 238 |
| abdominal pain upperSignal | 6 | 10.8 | 5.0 | 44 |
| off label useSignal | 25 | 10.5 | 7.9 | 215 |
| therapeutic product effect incomplete | 2 | 10.4 | 2.7 | 9 |
| intentional product misuse | 2 | 8.4 | 2.2 | 7 |
| diarrhoeaSignal | 14 | 8.0 | 5.1 | 81 |
| abdominal discomfort | 2 | 4.4 | 1.1 | 2 |
| product dose omission issue | 3 | 3.8 | 1.3 | 4 |
| abdominal distension | 1 | 3.5 | 0.5 | 0 |
| constipation | 2 | 3.4 | 0.9 | 1 |
| pruritus | 3 | 2.9 | 1.0 | 2 |
| drug ineffectiveSignal | 9 | 2.5 | 1.4 | 7 |
| nausea | 4 | 1.9 | 0.7 | 1 |
| abdominal pain | 1 | 1.6 | 0.2 | 0 |
| vomiting | 2 | 1.6 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.